- New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.
- Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases.
- Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD.
[1] Seretide® and Diskus® are registered trademarks owned by Glaxo Group Ltd.
Holzkirchen, August 31, 2016 – New data just …